Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel ...

Please provide your email address to receive an email when new articles are posted on . Aura Biosciences has reached an agreement with the FDA for a study design investigating belzupacap sarotalocan ...

Please provide your email address to receive an email when new articles are posted on . PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jill Hopkins, MD, of Aura ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

Aura Biosciences, Inc. (AURA) has been able to advance its pipeline with great clinical success in the last several months. That's because it has been able to report positive results from two studies ...

Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating ...